Chemotherapy of Late Stage Breast Cancer Targeted Towards Cell Cycle Regulatory Components
Abstract
We have investigated two drugs which target cell cycle regulatory components as potential cancer chemotherapeutic agents for use in late stage breast cancer. The first, 5,6-dihydro-5-azacytidine (DHAC), a DNA methylation inhibitor, has been tested for its potential to reduce unregulated growth in cultured breast cancer cell lines which fail to express the cyclin-dependent kinase inhibitor protein p16 due to p16 gene methylation. DHAC was found to significantly affect the growth and cell cycle distribution of cultured T47-D breast cancer cells. However, this was not accompanied by detectable expression of p16 protein in these cells. We are currently employing a related methylation inhibitor, 5-aza-2 deoxycytidine, in attempts to optimize conditions for promotion of detectable p16 expression, since this has the potential to produce greater reductions in cell growth as well as in tumorigenic properties. The second drug studied, bryostatin-1, promotes expression of another type of cyclin-dependent kinase inhibitor, p21.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA384617
Entities
People
- Thomas Langan
Organizations
- University of Colorado Health